Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 30, 2020

Primary Completion Date

March 12, 2025

Study Completion Date

July 10, 2026

Conditions
Malignant Solid NeoplasmRefractory CholangiocarcinomaRefractory Malignant Solid Neoplasm
Interventions
PROCEDURE

Biopsy Procedure

Undergo tumor biopsies

PROCEDURE

Biospecimen Collection

Undergo collection of blood

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

DRUG

Ceralasertib

Given PO

PROCEDURE

Computed Tomography

Undergo CT scans

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI scans

DRUG

Olaparib

Given PO

Trial Locations (13)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

32610

University of Florida Health Science Center - Gainesville, Gainesville

35233

University of Alabama at Birmingham Cancer Center, Birmingham

43210

Ohio State University Comprehensive Cancer Center, Columbus

48201

Wayne State University/Karmanos Cancer Institute, Detroit

48334

Weisberg Cancer Treatment Center, Farmington Hills

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

60611

Northwestern University, Chicago

77030

M D Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

06510

Smilow Cancer Center/Yale-New Haven Hospital, New Haven

06520

Yale University, New Haven

06611

Smilow Cancer Hospital Care Center-Trumbull, Trumbull

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH